Improving Global Health
Faculty researchers at the Vaccine Testing Center (VTC) study new human vaccines with the ultimate goal of understanding and preventing infectious diseases around the globe. Our team is particularly interested in new vaccines with the potential to prevent or control infectious diseases in developing countries. VTC is a diverse team of clinicians, study coordinators, scientists, and laboratory personnel. Volunteers are critical to our work, and our human research studies are carefully designed and performed with rigorous oversight in the safest possible manner. All studies are approved by the ethics review board (Institutional Review Board, IRB) of the University of Vermont.
Volunteers are central to the mission of the Vaccine Testing Center. At this time, we are not recruiting volunteers for inpatient or outpatient vaccine trials. Click here for more information.
The Vaccine Testing Center team runs a fully functioning unit for performing phase I and II vaccine trials and enteric challenge models. In general, the VTC focuses on the development of vaccines of importance to global health, including rotavirus, typhoid fever, Campylobacter and cholera infections, as well as dengue and other flavivirus diseases.
A recently published article in Science Translational Medicine highlighted the VTC's involvement in clinical trials for a highly effective, single-dose dengue vaccine. Read more on the ground-breaking results here.
The Vaccine Testing Center Cryptosporidum study team received a $3.3 million grant from the Bill & Melinda Gates Foundation to test new therapeutic agents. Read the full article here.
UVM Vaccine Testing Center answers questions regarding the recent Zika outbreak and the work that will be done here at UVM to assist in developing a vaccine for it.
Researcher/Analyst Ross Colgate of the UVM Vaccine Testing Center was interviewed on VPR Vermont Edition regarding the VTC's recent Rotavirus immunology award. Listen to the full interview here.
UVM Vaccine Testing Center receives grant for Rotavirus immunology study from the Bill and Melinda Gates Foundation. For the full article, click here.
Last modified March 22 2016 01:08 PM